European Pharmaceutical Review

OCTOBER 19, 2022

2 Recently, the US Patent and Trademark Office (US PTO) reiterated the concern that patents have been “misused to inhibit and delay – for years and even decades – competition from generic drugs and biosimilars, denying Americans access to lower-cost drugs.” Patents are often described as the ‘lifeblood’ of pharmaceutical companies.

Food and Drug Administration 96

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA 96

European Pharmaceutical Review

JANUARY 31, 2025

By the end of the decade, two cell and gene therapies will be subject to follow-on competition for the first time, beginning a whole new chapter in the biosimilar history. Over time, patient volumes (patient treatment days) and levels of competition, including market share, were also considered. 6 billion in 2024 alone).

Medicine 52

Medicine Competition Marketing Patients 52

pharmaphorum

JANUARY 16, 2023

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. And all are predominantly prevented or treated with medicines that are decades old. About the author.

FDA 98

FDA Healthcare Healthcare Medicine 98